Justin M Oldham1, Cathryn Lee2, Eleanor Valenzi3, Leah J Witt4, Ayodeji Adegunsoye4, Scully Hsu4, Lena Chen4, Steven Montner5, Jonathan H Chung5, Imre Noth4, Rekha Vij4, Mary E Strek4. 1. Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, The University of California at Davis, United States. Electronic address: joldham@ucdavis.edu. 2. Department of Medicine, The University of Chicago, United States. 3. Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, The University of Pittsburgh, United States. 4. Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, United States. 5. Department of Radiology, The University of Chicago, United States.
Abstract
BACKGROUND: Azathioprine is a commonly prescribed therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). Combination therapy that included azathioprine was recently shown to increase the risk of death and hospitalization in patients with idiopathic pulmonary fibrosis. Whether azathioprine increases the risk of adverse outcomes in patients with fibrotic CTD-ILD, including those with CTD-associated usual interstitial pneumonia (UIP), remains unknown. METHODS: A retrospective cohort analysis was performed to determine the combined incidence rate of death, transplant and respiratory hospitalization associated with azathioprine exposure. A fibrotic CTD-ILD cohort treated with mycophenolate mofetil served as a comparator group. Incidence rates were compared with an incidence rate ratio (IRR) generated by negative binomial regression. Longitudinal pulmonary function response was then assessed using mixed effects linear regression models. RESULTS: Fifty-four patients were treated with azathioprine and forty-three with mycophenolate. Medication discontinuation due to non-respiratory side effects occurred in 27% and 5% of the azathioprine and mycophenolate cohorts, respectively. The combined incidence rate of adverse outcomes was 0.015 and 0.013 for azathioprine and mycophenolate, respectively (IRR 1.23; 95% CI 0.49-3.12; p = 0.66). Similar incidence rates were observed among those with CTD-UIP (IRR 0.83; 95% CI 0.21-3.31; p = 0.79). Both groups demonstrated pulmonary function stability over time, with the azathioprine group demonstrating a marginal improvement. CONCLUSIONS: A significant minority of patients could not tolerate azathioprine due to non-respiratory side effects. Of those who did tolerate azathioprine, a similar incidence of adverse outcomes was observed as those treated with mycophenolate. Both therapies were associated with stability in pulmonary function. Copyright Â
BACKGROUND:Azathioprine is a commonly prescribed therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). Combination therapy that included azathioprine was recently shown to increase the risk of death and hospitalization in patients with idiopathic pulmonary fibrosis. Whether azathioprine increases the risk of adverse outcomes in patients with fibrotic CTD-ILD, including those with CTD-associated usual interstitial pneumonia (UIP), remains unknown. METHODS: A retrospective cohort analysis was performed to determine the combined incidence rate of death, transplant and respiratory hospitalization associated with azathioprine exposure. A fibrotic CTD-ILD cohort treated with mycophenolate mofetil served as a comparator group. Incidence rates were compared with an incidence rate ratio (IRR) generated by negative binomial regression. Longitudinal pulmonary function response was then assessed using mixed effects linear regression models. RESULTS: Fifty-four patients were treated with azathioprine and forty-three with mycophenolate. Medication discontinuation due to non-respiratory side effects occurred in 27% and 5% of the azathioprine and mycophenolate cohorts, respectively. The combined incidence rate of adverse outcomes was 0.015 and 0.013 for azathioprine and mycophenolate, respectively (IRR 1.23; 95% CI 0.49-3.12; p = 0.66). Similar incidence rates were observed among those with CTD-UIP (IRR 0.83; 95% CI 0.21-3.31; p = 0.79). Both groups demonstrated pulmonary function stability over time, with the azathioprine group demonstrating a marginal improvement. CONCLUSIONS: A significant minority of patients could not tolerate azathioprine due to non-respiratory side effects. Of those who did tolerate azathioprine, a similar incidence of adverse outcomes was observed as those treated with mycophenolate. Both therapies were associated with stability in pulmonary function. Copyright Â
Authors: E J Kim; B M Elicker; F Maldonado; W R Webb; J H Ryu; J H Van Uden; J S Lee; T E King; H R Collard Journal: Eur Respir J Date: 2009-12-08 Impact factor: 16.671
Authors: Jeffrey J Swigris; Amy L Olson; Aryeh Fischer; David A Lynch; Gregory P Cosgrove; Stephen K Frankel; Richard T Meehan; Kevin K Brown Journal: Chest Date: 2006-07 Impact factor: 9.410
Authors: D Deheinzelin; V L Capelozzi; R A Kairalla; J V Barbas Filho; P H Saldiva; C R de Carvalho Journal: Am J Respir Crit Care Med Date: 1996-09 Impact factor: 21.405
Authors: Aryeh Fischer; Kevin K Brown; Roland M Du Bois; Stephen K Frankel; Gregory P Cosgrove; Evans R Fernandez-Perez; Tristan J Huie; Mahalakshmi Krishnamoorthy; Richard T Meehan; Amy L Olson; Joshua J Solomon; Jeffrey J Swigris Journal: J Rheumatol Date: 2013-03-01 Impact factor: 4.666
Authors: Julio A Huapaya; Leann Silhan; Iago Pinal-Fernandez; Maria Casal-Dominguez; Cheilonda Johnson; Jemima Albayda; Julie J Paik; Abanti Sanyal; Andrew L Mammen; Lisa Christopher-Stine; Sonye K Danoff Journal: Chest Date: 2019-06-22 Impact factor: 9.410
Authors: Ana Catarina Duarte; Ana Cordeiro; Bruno Miguel Fernandes; Miguel Bernardes; Patrícia Martins; Inês Cordeiro; Tânia Santiago; Maria Inês Seixas; Ana Roxo Ribeiro; Maria José Santos Journal: Clin Rheumatol Date: 2019-04-23 Impact factor: 2.980
Authors: Sicong Huang; Vanessa L Kronzer; Paul F Dellaripa; Kevin D Deane; Marcy B Bolster; Vivek Nagaraja; Dinesh Khanna; Tracy J Doyle; Jeffrey A Sparks Journal: Curr Treatm Opt Rheumatol Date: 2020-09-01
Authors: Julia Graham; Iazsmin Bauer Ventura; Chad A Newton; Cathryn Lee; Noelle Boctor; Janelle Vu Pugashetti; Claire Cutting; Elena Joerns; Habrinder Sandhu; Jonathan H Chung; Christine Kim Garcia; Michael Kadoch; Imre Noth; Ayodeji Adegunsoye; Mary E Strek; Justin M Oldham Journal: Eur Respir J Date: 2020-07-16 Impact factor: 16.671